Search

Your search keyword '"Wiedemann GJ"' showing total 52 results

Search Constraints

Start Over You searched for: Author "Wiedemann GJ" Remove constraint Author: "Wiedemann GJ"
52 results on '"Wiedemann GJ"'

Search Results

1. Sinn und Unsinn von Tumormarkern in der Krebsfrüherkennung

Catalog

Books, media, physical & digital resources

5. [Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)].

6. Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.

7. A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma.

9. Hyperthermia and mafosfamide in a human-derived malignant pleural mesothelioma cell line.

10. [Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].

11. Ureteric and pulmonary endometriosis.

12. Modulation of VP-16 cytotoxicity by carboplatin and 41.8 degrees C hyperthermia.

13. A preclinical model for experimental chemotherapy of human head and neck cancer.

14. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer.

15. Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease.

16. Advanced non-seminomatous germ cell cancer of the testis with brain metastases: feasibility of additional brain irradiation and whole body hyperthermia plus chemotherapy.

17. Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia.

18. An animal model for anaplastic large cell lymphoma in the immunocompetent syngeneic C57Bl/6 mouse.

19. [Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].

20. [Whole-body hyperthermia: global warming in tumor therapy?].

21. Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia.

22. [New immunotherapeutic approaches for the treatment of anaplastic large cell lymphoma in a mouse model].

23. Ischemic stroke due to transient thrombosis of the internal carotid artery in a patient with combined antiphospholipid syndrome and factor V Leiden.

24. Trofosfamide in patients with pancreatic cancer.

25. Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy.

26. [Rationing in public health: what criteria, what priorities?].

27. Heat shock protein antibodies in sarcoma patients undergoing 41.8 degrees C whole body hyperthermia.

28. Treatment of unresectable carcinoma of the esophagus or the gastroesophageal junction by mesh stents with or without radiochemotherapy.

29. [Vascular endothelial growth factor VEGF stimulates angiogenesis in good and bad situations].

30. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.

31. Familial coexistence of primary antiphospholipid syndrome and factor VLeiden.

32. Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity.

33. Influence of circadian rhythm on 41.8 degrees C whole body hyperthermia induction of haematopoietic growth factors.

34. Dynamic changes in serum erythropoietin levels in solid tumour patients undergoing 41.8 degrees C whole body hyperthermia and/or chemotherapy.

36. Systemic hyperthermia and ICE chemotherapy for sarcoma patients: rationale and clinical status.

37. Serum thrombopoietin and interleukin 6 concentrations in tumour patients and response to chemotherapy-induced thrombocytopenia.

38. Rationale and clinical status of local hyperthermia, radiation, and chemotherapy in locally advanced malignancies.

39. Optimization of chemotherapy administration for clinical 41.8 degrees C whole body hyperthermia.

40. [Quality in hospital treatment. How is it assured and who determines the guidelines?].

42. In vitro studies of the hyperthermic enhancement of activated ifosfamide (4-hydroperoxy-ifosfamide) and glucose isophosphoramide mustard.

43. [Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia].

44. Local hyperthermia, radiation, and chemotherapy in locally advanced malignancies.

45. Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma.

46. Cytokine induction by 41.8 degrees C whole body hyperthermia.

48. [Endocrine therapy of progressive breast carcinoma].

49. [Hyperthermia in metastasizing breast carcinoma].

50. Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma.